New blood test aims to spot liver cancer recurrence early

NCT ID NCT07466602

Recruiting now Diagnosis Sponsor: Wuhan Ammunition Life-tech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a blood test that looks for specific gene changes (methylation of GNB4 and Riplet genes) to see if it can detect when primary liver cancer comes back after treatment. The trial will follow 500 patients who had surgery, transplant, ablation, or chemoembolization. The test's accuracy will be compared to standard clinical diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: plasma GNB4 and Riplet genes methylation detection
What this could lead to: If successful, this blood test could help doctors catch liver cancer recurrence earlier, potentially improving treatment timing and outcomes.
What could go wrong: This is a diagnostic accuracy study, not a treatment trial. The test may not be more effective than current monitoring methods, and results need validation in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY LIVER CANCER

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.